Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says

An endpoint of progression-free survival is appropriate for full approval of first-line non-small cell lung cancer treatments in metastatic cancers, but not for earlier-stage disease, the Oncologic Drugs Advisory Committee concluded Dec. 16